Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Revelation is a clinical-stage biotechnology company developing the Gemini platform, a proprietary formulation of PHAD (a TLR4 agonist) designed to rebalance inflammation. The company's lead programs are GEM-AKI (Acute Kidney Injury) and GEM-CKD (Chronic Kidney Disease). The company has no approved products and has incurred net losses since inception.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8.9) million | $(15.0) million |
| Accumulated Deficit | $(49.4) million | $(40.5) million |
| Cash and Cash Equivalents (Year-End) | $10.7 million | $6.5 million |
| Net Cash Used in Operating Activities | $(8.3) million | $(18.3) million |
| Net Cash Provided by Financing Activities | $12.5 million | $12.8 million |
| Stockholders' Equity | $8.9 million | $4.7 million |
Note: The filing does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $6.1 million (40%) from 2024 to 2025. This improvement was primarily driven by a significant reduction in "Other income (expense), net," which shifted from a $7.1 million expense in 2024 (due to legal judgments and settlement costs) to a $0.2 million income in 2025.
- Operating Expenses: Total operating expenses increased by $1.1 million to $9.1 million. Research and Development (R&D) expenses rose by $0.5 million, and General and Administrative (G&A) expenses rose by $0.6 million, reflecting continued clinical development and public company compliance costs.
- Capital Structure: The company executed multiple reverse stock splits in 2024 and 2025 (1-for-30, 1-for-16, and 1-for-3) to maintain Nasdaq listing compliance. A 1-for-4 reverse split was effected in January 2026 (subsequent to year-end).
- Financing Activity: In 2025, the company raised approximately $12.5 million through a public offering and warrant inducement exercises, compared to $12.8 million in 2024.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
The audited financial statements contain a going concern qualification. Management states that current cash ($10.7 million) plus subsequent proceeds ($6.7 million from a January 2026 warrant inducement) will not be sufficient to sustain operations for one year after the issuance of the financial statements. The company anticipates needing additional funding to continue its business.
Outlook and Development Plans
- GEM-AKI: The company obtained FDA agreement on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis. Plans for 2026 include building infrastructure (scientific advisory board, CRO engagement) to start the study.
- GEM-CKD: The company intends to conduct preclinical toxicology studies in 2026 to support a repeat-dose Phase 2 study.
Key Risks and Contingencies
- Regulatory Uncertainty: Risks related to FDA staffing reductions and policy changes under the 2025 Trump Administration, including potential tariffs on imported drugs and "Most-Favored-Nation" pricing mandates, could increase costs and delay approvals.
- Supply Chain: Reliance on a single supplier (Avanti Polar Lipids, Inc.) for the active pharmaceutical ingredient (PHAD) without a long-term supply agreement.
- Listing Status: The company faces risks regarding continued listing on Nasdaq due to market value and equity requirements.
- Unusual Items (2024): The 2024 net loss was significantly impacted by a LifeSci Capital LLC judgment expense and clinical trial settlement expenses, which were not present in 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.4 million total liquidity (year-end cash + subsequent warrant proceeds) against the projected burn rate for the upcoming Phase 2/3 study.
- Financing Terms: Review the terms of the January 2026 warrant inducement and any subsequent financing to assess dilution impact on existing shareholders.
- Regulatory Milestones: Monitor the timeline for the initiation of the GEM-AKI Phase 2/3 study and the impact of new 2025 federal executive orders on drug pricing and manufacturing.
- Supplier Agreements: Confirm if a long-term supply agreement has been secured with Avanti Polar Lipids, Inc. to mitigate single-source risk.
- Nasdaq Compliance: Track the company's progress in meeting Nasdaq minimum bid price and market value of publicly held shares requirements to avoid delisting.